3/21/2024 0 Comments Moca test pdf françaisThis present study addresses the current gap of cognitive assessment tools specific to cancer survivors as defined by the American Cancer Society by presenting a novel tool developed specifically with persons with cancer. This limitation is of great importance since patients with cancer are expected to show better cognitive ability than patients with dementia as they do not present with widespread organic brain degeneration. These results confirmed the conclusions of other authors. Although these tools are more time-efficient, our group has previously demonstrated that the MoCA, when administered to persons with cancer, presents a noticeable ceiling effect, meaning that it cannot detect subtle cognitive deficits. The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) have been used for decades as cognitive screening tools in the geriatric population for suspected dementia and more recently, in other populations. Currently available cognitive assessment tests such as the Repeatable Battery for the Assessment of Neuropsychological status and the High Sensitivity Cognitive Screen are too time-intensive to be used in everyday clinical practice. Presently, there is a lack of cognitive screening tools applicable to CRCI adapted to the clinical setting and none are specific to this population, nor can they detect the subtle cognitive changes seen in CRCI, detect them early, and evaluate them over time (before, during, and after the course of treatment). The first step in treating any condition, including CRCI, is the ability to detect its occurrence. CRCI is described as a syndrome presenting as a combination of difficulties with working memory, decreased concentration, attention deficits, reduced verbal fluency, and impaired executive function. Unfortunately, CRCI remains underdiagnosed and challenging to treat. CRCI was first recognized by cancer survivors themselves and is estimated to affect 75% of patients during treatment and approximately 25-35% years after treatment. Cancer-related cognitive impairment (CRCI) is amongst the most troublesome, as it not only affects patients’ quality of life, but also significantly limits their daily and social functioning including their return to active professional life. Although survival rates have risen, cancer is often accompanied by secondary symptomatology from the malignancy itself or its treatments, months, or years into remission. It is reported that the 5- and 10-year average survival rates for persons with cancer, all cancers combined, are 63% and 57%, respectively. In 2020, the Canadian Cancer Society estimated that 225,800 Canadians were diagnosed with cancer. In addition, FaCE could be used as a measurement tool in research exploring cognitive disorders in cancer survivors. This can contribute to early and appropriate interventions for better quality of life in patients with CRCI. Within the average testing time of five minutes, FaCE assesses the main cognitive domains affected in CRCI.įaCE is a rapid, reliable, and sensitive tool for detecting even minimal cognitive changes over time. ![]() FaCE’s scale is accurate (reliable) with high discriminant ability between cognitive levels. Person-reliability (0.65) and person-separation (1.37) indexes indicate excellent internal consistency. The population size was large enough to test the set of items (item-reliability-index=0.96). FaCE was developed using Rasch Measurement Theory, a model that establishes the conditions for a measurement tool to be considered a rating scale.įaCE shows excellent psychometric properties. This study addresses this lack of cognitive screening tools by developing a novel tool, the Fast Cognitive Evaluation (FaCE).Ī population of 245 patients with 11 types of cancer at different illness and treatment time-points was enrolled for the analysis. ![]() Importantly, although shorter, screening tools such as the Montreal Cognitive Assessment or the Mini-Mental State Evaluation have demonstrated a ceiling effect in persons with cancer, and thus fail to detect subtle cognitive changes expected in patients with CRCI. Available cognitive assessment tools are too time consuming for day-to-day clinical setting assessments. ![]() Cancer-related cognitive impairment (CRCI) is one of the most concerning conditions experienced by patients living with cancer and has a major impact on their quality of life.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |